These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34247853)

  • 1. Omalizumab in chronic inducible urticaria: A retrospective, real-life study.
    Fialek M; Dezoteux F; Le Moing A; Karimova E; Ramdane N; Pape E; Azib-Meftah S; Staumont-Sallé D
    Ann Dermatol Venereol; 2021 Dec; 148(4):262-265. PubMed ID: 34247853
    [No Abstract]   [Full Text] [Related]  

  • 2. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
    Skander D; Allenova A; Maurer M; Kolkhir P
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of Omalizumab in Patients with Chronic Inducible Urticaria: real-life experience from two UCARE centres.
    Can PK; Salman A; Hoşgören-Tekin S; Kocatürk E
    J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e679-e682. PubMed ID: 34013560
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness and tolerability of personalized omalizumab treatment in patients with chronic inducible urticaria.
    Buters TP; van der Velden WAC; Abdisalaam I; van Maaren MS; van Doorn MBA
    J Allergy Clin Immunol Pract; 2021 Aug; 9(8):3227-3229. PubMed ID: 33915307
    [No Abstract]   [Full Text] [Related]  

  • 5. Omalizumab in children and adolescents with chronic urticaria: A 16-week real-world study.
    Song XT; Chen YD; Yu M; Liu B; Zhao ZT; Maurer M
    Allergy; 2021 Apr; 76(4):1271-1273. PubMed ID: 33275779
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of additional treatment for chronic spontaneous urticaria refractory to treatment - A single-center retrospective real-world study.
    Ohata M; Oda Y; Washio K; Fukunaga A; Nishigori C
    J Dermatol; 2022 Jan; 49(1):e7-e8. PubMed ID: 34632611
    [No Abstract]   [Full Text] [Related]  

  • 7. Omalizumab in Chronic Urticaria: An Italian Survey.
    Damiani G; Diani M; Conic RRZ; Colli L; Ferrucci S; Martina E; Offidani AM; Pigatto PDM
    Int Arch Allergy Immunol; 2019; 178(1):45-49. PubMed ID: 30396176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HOW PERIPHERAL BASOPHILS IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA ARE CHANGED WITH OMALIZUMAB TREATMENT?].
    Oda Y; Washio K; Mizuno M; Imamura S; Nishigori C; Fukunaga A
    Arerugi; 2021; 70(9):1196-1199. PubMed ID: 34759084
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of omalizumab in chronic spontaneous urticaria associated with chronic inducible urticaria.
    Dortas Junior S; Azizi G; Valle S
    Ann Allergy Asthma Immunol; 2020 Oct; 125(4):486-487. PubMed ID: 32544531
    [No Abstract]   [Full Text] [Related]  

  • 10. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders?
    Asero R
    Eur Ann Allergy Clin Immunol; 2021 Jan; 53(1):47-48. PubMed ID: 32378398
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria: a single-center experience.
    Akdaş E; Adışen E; Öztaş MO; Aksakal AB; İlter N; Gülekon A
    An Bras Dermatol; 2023; 98(2):240-242. PubMed ID: 36567165
    [No Abstract]   [Full Text] [Related]  

  • 12. Omalizumab in cold urticaria in children: Retrospective case series of 13 patients, review of the literature.
    Briand C; Tetart F; Soria A; Staumont-Sallé D; Sterling B; Boralevi F; Castelain Lakkis F; Du-Thanh A; Raison-Peyron N; Chiaverini C
    Ann Dermatol Venereol; 2021 Dec; 148(4):269-271. PubMed ID: 34503855
    [No Abstract]   [Full Text] [Related]  

  • 13. Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study.
    Abduelmula A; Georgakopoulos JR; Mufti A; Devani AR; Gooderham MJ; Hong CH; Jain V; Lansang P; Vender R; Prajapati VH; Yeung J
    J Cutan Med Surg; 2022; 26(3):319-320. PubMed ID: 34587789
    [No Abstract]   [Full Text] [Related]  

  • 14. Omalizumab in chronic inducible urticaria: A real-life study of efficacy, safety, predictors of treatment outcome and time to response.
    Yu M; Terhorst-Molawi D; Altrichter S; Hawro T; Chen YD; Liu B; Song XT; Zhao ZT; Maurer M
    Clin Exp Allergy; 2021 May; 51(5):730-734. PubMed ID: 33522024
    [No Abstract]   [Full Text] [Related]  

  • 15. "Omalizumab plus": Combining omalizumab with immunosuppression for treatment of refractory chronic urticaria: A multicenter UK series.
    Rutkowski K; Wagner A; Jui-Lin Choo K; Smith H; Savic S; Grattan CE
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1400-1401.e2. PubMed ID: 33181342
    [No Abstract]   [Full Text] [Related]  

  • 16. Effective omalizumab interval prolongation in the treatment of chronic urticaria.
    Alizadeh Aghdam M; Pieterse RH; Kentie PA; Rijken F; Knulst AC; Röckmann H
    J Allergy Clin Immunol Pract; 2020; 8(10):3667-3668.e1. PubMed ID: 32679351
    [No Abstract]   [Full Text] [Related]  

  • 17. High-dose omalizumab use in patients with chronic spontaneous urticaria.
    Alizadeh Aghdam M; van den Broek F; Rijken F; Knulst AC; Röckmann H
    J Allergy Clin Immunol Pract; 2020 Apr; 8(4):1426-1427.e1. PubMed ID: 31678293
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical predictive factors of unresponsiveness to omalizumab in patients with chronic spontaneous urticaria.
    Castagna J; Bernard L; Hacard F; Delcroix F; Darrigade AS; Nicolas JF; Decullier E; Nosbaum A; Bérard F
    Br J Dermatol; 2020 Dec; 183(6):1124-1126. PubMed ID: 32531805
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclosporine and omalizumab together: A new option for chronic refractory urticaria.
    Sánchez J; Alvarez L; Cardona R
    J Allergy Clin Immunol Pract; 2020 Jun; 8(6):2101-2103. PubMed ID: 32112923
    [No Abstract]   [Full Text] [Related]  

  • 20. Duration of chronic spontaneous urticaria remission after omalizumab discontinuation: A long-term observational study.
    Di Bona D; Nettis E; Bilancia M; Ridolo E; Minenna E; Nizi MC; Albanesi M; Caiaffa MF; Macchia L
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2482-2485.e2. PubMed ID: 33677081
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.